English Spanish Chinese Russian French Japanese Portuguese Hindi Telugu Tamil

Archives of Clinical Microbiology

  • ISSN: 1989-8436
  • H-Index der Zeitschrift: 22
  • Zitierbewertung der Zeitschrift: 7.55
  • Journal-Impact-Faktor: 6.38
Indiziert in
  • Öffnen Sie das J-Tor
  • Genamics JournalSeek
  • Der Global Impact Factor (GIF)
  • Open-Archive-Initiative
  • Nationale Wissensinfrastruktur Chinas (CNKI)
  • Verzeichnis der Indexierung von Forschungszeitschriften (DRJI)
  • OCLC – WorldCat
  • Proquest-Vorladungen
  • Publons
  • MIAR
  • Kommission für Universitätsstipendien
  • Genfer Stiftung für medizinische Ausbildung und Forschung
  • Google Scholar
  • Scimago Journal-Ranking
  • Geheime Suchmaschinenlabore
  • ResearchGate
Mehr sehen
Teile diese Seite

Abstrakt

Brief Overview on "Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture"

Warren K. Weston*,Jane A. Harness and Aarthi Narayanan

The COVID-19 pandemic remains a pressing global challenge. Worldwide mortality attributable to COVID-19 now exceeds 4 million deaths. There is an urgent need for developing novel therapeutics to treat SARS-CoV-2. Our recent study showed brilacidin, a synthetic small molecule with peptide-like properties, potently inhibits SARS-CoV-2 in cell culture. Additionally, brilacidin exhibited in vitro inhibition in combination with remdesivir, the only FDA-approved drug for treatment of COVID-19. Brilacidin is currently undergoing Phase 2 clinical testing for treatment of moderate-to-severe COVID-19 in hospitalized patients.